If you have not received the news release or if you would like to be added to the company’s distribution list, please email your request to This call is being broadcast live over the Internet on the company’s website at and a replay of the call will be available on the website for the next 90 days. As a reminder, this conference call is being recorded today, July 22, 2015, and contains time-sensitive information that is accurate only as of today.Įarlier today, Natus Medical released financial results for the second quarter 2015. Later, we will conduct a question-and-answer session. At this time, all participants are in listen-only mode. Welcome to the Natus Medical Second Quarter 2015 Financial Results Conference Call. Ladies and gentlemen, thank you for standing by.
Larry Haimovitch - Haimovitch Medical Technology Consultants Jonathan Kennedy - SVP of Finance and CFOīrian Weinstein - William Blair & Company (BABY) Q2 2015 Earnings Conference Call J11:00 AM ET OraSure Technologies receives $8.Natus Medical, Inc.Teleflex completes $170M Standard Bariatrics acquisition.Johnson & Johnson Vision launches overnight, intraocular lenses.7 innovative digital health offerings to treat diabetes.Olympus launches Thunderbeat surgical energy devices.This robotic capsule could deliver large-protein drugs like insulin.FDA clears Nexpowder endoscopic hemostasis system from Medtronic.How Medtronic designed the next generation of GI bleeding treatment.Align Technology launches AI-powered home monitoring for Invisalign clear teeth aligners.
#NICVIEW NATUS UPDATE#
#NICVIEW NATUS SOFTWARE#
FDA clears next-gen deep learning MRI software from GE Healthcare.Invacare receives notice of noncompliance on NYSE share price listing rule.New medical device user fees agreement passes Congress.Precision Molding: Getting it Right the First Time.MassDevice’s MedTech 100 Index - which includes stocks of the world’s largest medical device companies - was up 1.1%.įiled Under: Business/Financial News, Diagnostics, MassDevice Earnings Roundup, Patient Monitoring, Pediatrics, Wall Street Beat Tagged With: coronavirus, COVID-19, Natus Medical Inc. NTUS shares were down -4.8% at $17.69 per share in midday trading today. Natus will continue to withhold its 2020 financial guidance at this time due to the uncertainties caused by the pandemic. We see our customers adapting to the COVID environment with elective procedures resuming, which we believe will result in increased capital spending, improving our business over the remainder of 2020.” We expect newborn care to remain closer to historical levels. “Looking ahead to the third quarter, we expect neuro and hearing & balance revenues to remain below pre-pandemic levels, but to improve compared to the second quarter. “As expected, we saw significant impact from COVID-19 during the second quarter, with revenue declining 32.5% compared to the second quarter of 2019,” Natus president & CEO Jonathan Kennedy said in a news release.
0 kommentar(er)
